GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases, has announced it will release its second quarter 2024 financial results on Tuesday, August 6, 2024, after U.S. markets close. The company will host a live conference call and webcast at 4:30 p.m. ET on the same day to discuss the financial results and provide a corporate update.
Investors and interested parties can join the conference call using the following details:
- Domestic: (800) 715-9871
- International: +1 (646) 307-1963
- Conference ID: 3852178
A webcast of the call will be available at https://edge.media-server.com/mmc/p/qj3e68n8, with a replay accessible for three months after the event.
GeoVax Labs, Inc. (Nasdaq: GOVX), un'azienda di biotecnologie in fase clinica focalizzata sullo sviluppo di immunoterapie e vaccini per il cancro e le malattie infettive, ha annunciato il rilascio dei suoi risultati finanziari del secondo trimestre 2024 martedì 6 agosto 2024, dopo la chiusura dei mercati statunitensi. L'azienda ospiterà una conference call e webcast in diretta alle 16:30 ET nello stesso giorno per discutere dei risultati finanziari e fornire un aggiornamento aziendale.
Gli investitori e le parti interessate possono partecipare alla conference call utilizzando i seguenti dettagli:
- Nazionale: (800) 715-9871
- Internazionale: +1 (646) 307-1963
- ID Conferenza: 3852178
Un webcast della chiamata sarà disponibile su https://edge.media-server.com/mmc/p/qj3e68n8, con una riproduzione accessibile per tre mesi dopo l'evento.
GeoVax Labs, Inc. (Nasdaq: GOVX), una empresa de biotecnología en etapa clínica centrada en el desarrollo de inmunoterapias y vacunas para el cáncer y enfermedades infecciosas, ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 el martes 6 de agosto de 2024, después del cierre de los mercados en EE. UU. La empresa llevará a cabo una llamada de conferencia y webcast en vivo a las 4:30 p.m. ET el mismo día para discutir los resultados financieros y proporcionar una actualización corporativa.
Los inversores y partes interesadas pueden unirse a la llamada de conferencia utilizando los siguientes detalles:
- Nacional: (800) 715-9871
- Internacional: +1 (646) 307-1963
- ID de la Conferencia: 3852178
Una retransmisión del llamado estará disponible en https://edge.media-server.com/mmc/p/qj3e68n8, con una repetición accesible durante tres meses después del evento.
GeoVax Labs, Inc. (Nasdaq: GOVX)는 암과 감염병을 위한 면역요법 및 백신 개발에 중점을 둔 임상 단계의 생명공학 회사로, 2024년 2분기 재무 실적을 2024년 8월 6일 화요일 미국 시장이 닫힌 후 발표할 예정이라고 밝혔습니다. 회사는 같은 날 오후 4시 30분 ET에 재무 실적에 대한 논의와 기업 업데이트를 제공하기 위해 라이브 컨퍼런스 콜 및 웹캐스트를 개최할 것입니다.
투자자 및 이해관계자는 다음 세부 사항을 사용하여 컨퍼런스 콜에 참여할 수 있습니다:
- 국내: (800) 715-9871
- 국제: +1 (646) 307-1963
- 회의 ID: 3852178
전화를 통해 진행될 웹캐스트는 https://edge.media-server.com/mmc/p/qj3e68n8에서 제공되며, 이벤트 후 3개월 동안 재생 가능하게 됩니다.
GeoVax Labs, Inc. (Nasdaq: GOVX), une entreprise de biotechnologie en phase clinique axée sur le développement d'immunothérapies et de vaccins contre le cancer et les maladies infectieuses, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 le mardi 6 août 2024, après la fermeture des marchés américains. L'entreprise organisera une conférence téléphonique en direct et un webinaire à 16h30 ET le même jour pour discuter des résultats financiers et fournir une mise à jour de l'entreprise.
Les investisseurs et les parties intéressées peuvent participer à la conférence téléphonique en utilisant les détails suivants :
- National : (800) 715-9871
- International : +1 (646) 307-1963
- ID de la conférence : 3852178
Un webinaire de l'appel sera disponible à l'adresse https://edge.media-server.com/mmc/p/qj3e68n8, avec une rediffusion accessible pendant trois mois après l'événement.
GeoVax Labs, Inc. (Nasdaq: GOVX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Immuntherapien und Impfstoffen gegen Krebs und Infektionskrankheiten spezialisiert hat, hat angekündigt, dass es seine finanziellen Ergebnisse für das zweite Quartal 2024 am Dienstag, den 6. August 2024, nach Börsenschluss in den USA veröffentlichen wird. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Live-Konferenzschaltung und Webcast abhalten, um die finanziellen Ergebnisse zu diskutieren und ein Unternehmensupdate zu geben.
Investoren und Interessierte können an der Konferenzschaltung mit den folgenden Angaben teilnehmen:
- Inlandsanruf: (800) 715-9871
- International: +1 (646) 307-1963
- Konferenz-ID: 3852178
Ein Webcast des Anrufs wird unter https://edge.media-server.com/mmc/p/qj3e68n8 verfügbar sein, mit einem Zugriff auf die Wiederholung für drei Monate nach der Veranstaltung.
- None.
- None.
GeoVax to Host Conference Call at 4:30 PM ET
ATLANTA, GA, July 30, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it will report second quarter 2024 financial results on Tuesday, August 6, 2024, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results.
Conference Call Details
Domestic: (800) 715-9871
International: +1 (646) 307-1963
Conference ID: 3852178
Webcast: https://edge.media-server.com/mmc/p/qj3e68n8
A webcast replay of the call will be available for three months via the same link as the live webcast approximately two hours after the end of the call.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world’s most threatening infectious diseases and therapies for solid tumor cancers. The company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The Company has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
| Company Contact: | Investor Relations Contact: | Media Contact: | ||
| info@geovax.com | austin.murtagh@precisionaq.com | sr@roberts-communications.com | ||
| 678-384-7220 | 212-698-8696 | 202-779-0929 | ||
FAQ
When will GeoVax (GOVX) report its Q2 2024 financial results?
What time is GeoVax's (GOVX) Q2 2024 earnings conference call?
How can I access GeoVax's (GOVX) Q2 2024 earnings call?
Where can I find the webcast for GeoVax's (GOVX) Q2 2024 earnings call?
